Long-Term Experience of Subcutaneous Immunoglobulin Therapy in Pediatric Primary Immunodeficient Patients with Low and Normal Body Weight.
Sign Up to like & getrecommendations! Published in 2021 at "Journal of clinical immunology"
DOI: 10.1007/s10875-021-01144-x
Abstract: PURPOSE The aim was to review the compliance, side effects and effectiveness of subcutaneous immunoglobulin (SCIG) supplementation in patients with primary immunodeficiencies (PID) who had previously received intravenous immunoglobulin (IVIG) therapy and subsequently switched to… read more here.
Keywords: subcutaneous immunoglobulin; patients low; normal body; body weight ... See more keywords
Correlations Among Subcutaneous Immunoglobulin Dosage, Immunoglobulin G Serum Pre-infusional Levels and Body Mass Index in Primary Antibody Deficiency Patients: A Pooled Analysis from the SHIFT/IBIS Studies
Sign Up to like & getrecommendations! Published in 2020 at "Clinical Drug Investigation"
DOI: 10.1007/s40261-020-00885-8
Abstract: Background and Objective In recent years, two Italian non-interventional studies evaluated subcutaneous immunoglobulin (SCIG) treatment in patients affected by primary antibody deficiency (PAD). The SHIFT study considered patients who were treated with intravenous immunoglobulin (IVIG) or… read more here.
Keywords: trough levels; subcutaneous immunoglobulin; immunoglobulin; igg trough ... See more keywords
Long-term neurophysiological and clinical response in patients with chronic inflammatory demyelinating polyradiculoneuropathy treated with subcutaneous immunoglobulin
Sign Up to like & getrecommendations! Published in 2018 at "Clinical Neurophysiology"
DOI: 10.1016/j.clinph.2018.01.070
Abstract: OBJECTIVE To assess the long-term effects of subcutaneous immunoglobulin (SCIg) on neurophysiological and clinical parameters in patients affected by chronic inflammatory demyelinating polyradiculoneuropathy (CIDP). METHODS 16 drug-naïve CIDP patients, fulfilling the clinical and neurophysiological criteria… read more here.
Keywords: subcutaneous immunoglobulin; term; long term; treatment ... See more keywords
Electrophysiological testing in chronic inflammatory demyelinating polyneuropathy patients treated with subcutaneous immunoglobulin: The Polyneuropathy And Treatment with Hizentra (PATH) study
Sign Up to like & getrecommendations! Published in 2021 at "Clinical Neurophysiology"
DOI: 10.1016/j.clinph.2020.09.001
Abstract: OBJECTIVE To assess electrophysiology parameters that can reflect patients' clinical status and show changes in nerve function with treatment, in a study of subcutaneous immunoglobulin in chronic inflammatory demyelinating polyneuropathy. METHODS Nerve conduction studies (latency,… read more here.
Keywords: subcutaneous immunoglobulin; treatment; study; chronic inflammatory ... See more keywords
Phase 2 trial in acetylcholine receptor antibody‐positive myasthenia gravis of transition from intravenous to subcutaneous immunoglobulin: The MGSCIg study
Sign Up to like & getrecommendations! Published in 2023 at "European Journal of Neurology"
DOI: 10.1111/ene.15745
Abstract: Data on maintenance therapy with subcutaneous immunoglobulin (SCIg) in myasthenia gravis (MG) are limited. We report on transitioning acetylcholine receptor (AChR) antibody‐positive (Ab+) MG patients on stable intravenous immunoglobulin (IVIg) regimens as part of routine… read more here.
Keywords: antibody positive; immunoglobulin; acetylcholine receptor; myasthenia gravis ... See more keywords
P81: AN AUDIT OF SUBCUTANEOUS IMMUNOGLOBULIN REPLACEMENT THERAPY IN SYDNEY 3 YEARS EXPERIENCE IN A SINGLE CENTRE
Sign Up to like & getrecommendations! Published in 2017 at "Internal Medicine Journal"
DOI: 10.1111/imj.81_13578
Abstract: ple well defined hypo-echoic lesions were demonstrated within the bowel wall suggesting a lymphoma. A laparotomy was performed and a very thickened distal terminal ileum and caecum was noted. No bowel biopsies were obtained because… read more here.
Keywords: replacement; replacement therapy; subcutaneous immunoglobulin; immunoglobulin replacement ... See more keywords
Subcutaneous immunoglobulin use in immunoglobulin-naive patients with primary immunodeficiency: a systematic review.
Sign Up to like & getrecommendations! Published in 2022 at "Immunotherapy"
DOI: 10.2217/imt-2021-0265
Abstract: Aim: Identify and describe published literature on the use of subcutaneous immunoglobulin (SCIG) as initial immunoglobulin (IG)-replacement therapy for patients with primary immunodeficiency diseases (PID). Methods: We systematically identified and summarized literature in MEDLINE, Embase,… read more here.
Keywords: immunoglobulin; patients primary; naive patients; primary immunodeficiency ... See more keywords
Overview of subcutaneous immunoglobulin 16.5% in primary and secondary immunodeficiency diseases.
Sign Up to like & getrecommendations! Published in 2022 at "Immunotherapy"
DOI: 10.2217/imt-2021-0313
Abstract: Most primary immunodeficiency diseases, and select secondary immunodeficiency diseases, are treated with immunoglobulin (IG) therapy, administered intravenously or subcutaneously (SCIG). The first instance of IG replacement for primary immunodeficiency disease was a 16.5% formulation administered… read more here.
Keywords: overview subcutaneous; immunodeficiency diseases; secondary immunodeficiency; immunodeficiency ... See more keywords
Long-term safety of facilitated subcutaneous immunoglobulin treatment in pregnant women with primary immunodeficiency diseases: results from a registry study.
Sign Up to like & getrecommendations! Published in 2022 at "Immunotherapy"
DOI: 10.2217/imt-2021-0336
Abstract: Aim: Clinical outcomes of women who become pregnant during/after facilitated subcutaneous immunoglobulin (fSCIG) treatment are not well characterized. Materials & methods: This noninterventional, prospective, open-label, post authorization, pregnancy registry study assessed safety outcomes in mothers with… read more here.
Keywords: safety; facilitated subcutaneous; registry study; treatment ... See more keywords